NuVasive, Inc.  

(Public, NASDAQ:NUVA)   Watch this stock  
Find more results for NUVA
+0.01 (0.01%)
Oct 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 66.50 - 67.66
52 week 36.81 - 69.50
Open 66.96
Vol / Avg. 0.00/731,009.00
Mkt cap 3.39B
P/E 70.14
Div/yield     -
EPS 0.96
Shares 50.21M
Beta 0.51
Inst. own 107%
Oct 25, 2016
Q3 2016 NuVasive Inc Earnings Call - 5:30PM EDT - Add to calendar
Oct 25, 2016
Q3 2016 NuVasive Inc Earnings Release - 9:30AM EDT - Add to calendar
Sep 13, 2016
NuVasive Inc at Morgan Stanley Global Healthcare Conference
Sep 7, 2016
NuVasive Inc at Wells Fargo Securities Healthcare Conference
Jul 26, 2016
Q2 2016 NuVasive Inc Earnings Call - Webcast
Jul 26, 2016
Q2 2016 NuVasive Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin 12.61% 8.05%
Operating margin 25.43% 17.15%
EBITD margin - 21.17%
Return on average assets 7.53% 4.94%
Return on average equity 18.00% 9.81%
Employees 1,600 -
CDP Score - -


7475 Lusk Blvd
SAN DIEGO, CA 92121-5707
United States - Map
+1-858-9091800 (Phone)
+1-800-4759134 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company's spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company's biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.

Officers and directors

Gregory T. Lucier Chairman of the Board, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Jason M. Hannon President, Chief Operating Officer
Age: 44
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Matthew W. Link President - U.S. Commercial
Age: 41
Bio & Compensation  - Reuters
Patrick W. G. Miles Vice Chairman of the Board
Age: 50
Bio & Compensation  - Reuters
Quentin S. Blackford Chief Financial Officer, Executive Vice President
Age: 37
Bio & Compensation  - Reuters
Joan Stafslien Executive Vice President, General Counsel, Corporate Secretary
Bio & Compensation  - Reuters
Carol A. Cox Executive Vice President - External Affairs and Corporate Marketing
Age: 51
Bio & Compensation  - Reuters
Jason D. Hanson Executive Vice President - Strategy, Corporate Development and General Counsel
Age: 47
Bio & Compensation  - Reuters
Peter Michael Leddy Ph.D. Executive Vice President - Corporate Integrity and Global Human Resources
Age: 53
Bio & Compensation  - Reuters
Jack R. Blair Independent Director
Age: 73
Bio & Compensation  - Reuters